


PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	TBA 09/978,436
				Filing Date	Herewith 10-16-97
				Confirmation Number	TBA
				First Named Inventor	Robert A. Holton
				Group Art Unit	TBA 1625
				Examiner Name	TBA TMMH
Sheet	1	of	3	Attorney Docket No.	FSUM 10551.1

U.S. PTO
 09/978436
 10/16/01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
OT	32	5,250,683		Holton, et al.	10-05-1993
OT	33	5,283,253		Holton, et al.	02-01-1994
BT	34	5,648,506		Desai, et al.	07-15-1997

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AT	35✓	Tishler, et al., "Taxol: A Novel Radiation Sensitizer," Int. J. Radiat. Oncol. Biol. Phys., 1992, Vol. 22, pp. 613-617.	
A	36✓	Tishler, et al., "Taxol Sensitizes Human Astrocytoma Cells to Radiation," Cancer Res., 1992, Vol. 52, pp. 3495-3497	
OT	37✓	Steren, et al., "Taxol Sensitizes Human Ovarian Cancer Cells to Radiation," Gynecol. Oncol., 1993, Vol. 48, pp 252-258.	
AT	38✓	Steren, et al., "Taxol as a Radiation Sensitizer: A Flow Cytometric Study," Gynecol. Oncol., 1993, Vol. 50, pp. 89-93.	
BT	39✓	Hei, et al., "Taxol, Radiation, and Oncogenic Transformation," Gynecol. Oncol., 1993, Vol. 53, pp. 1368-1372.	

Examiner Signature		Date Considered	1-02
-----------------------	---	--------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

BEST AVAILABLE COPY

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	TBA 09/978,436
				Filing Date	Herewith 10.16.01
				Confirmation Number	TBA
				First Named Inventor	Robert A. Holton
				Group Art Unit	TBA 1625
				Examiner Name	TBA TRIN4
Sheet	2	of	3	Attorney Docket No.	FSUM 10596 / 055 R. 1

10/16/01
 09/978436
 U.S. PTO

ST	40	Liebmann, et al., "Changes in Radiation Survival Curve Parameters in Human Tumor and Rodent Cells Exposed to Paclitaxel (Taxol®)," Int. J. Radiat. Oncol. Biol. Phys., 1994, Vol. 29, No. 3, pp. 559-564.
ST	41	Liebmann, et al., "In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells," I. Natl. Cancer, 1994, Vol., 86, No. 6, pp. 441-446.
ST	42	Milas, et al., "Enhancement of Tumor Radioresponse of a Murine Mammary Carcinoma by Paclitaxel," Cancer Research, 1994, Vol. 54, pp. 3506-3510.
ST	43	Bocian, et al., "Sister chromatid exchanges induced by two radiosensitizing platinum compounds (cis-dichloro-bis isopropylamine transdihydroxy platinum IV (CHIP) and cis platinum metronoidaxole ₂ Cl ₂ (FLAP)) in CHO cells in vitro," Br. J. Cancer, 1983, Vol. 48, pp. 803-807.
ST	44	Teicher, et al., "Radiosensitization of EMT6 Cells by Four Platinum Complexes," Int. J. Radiat. Oncol. Biol. Phys., 1985, Vol. 11, pp. 937-941.
ST	45	Skov, et al., "Platinum Complexes with One Radiosensitizing Ligand [PtCl ₂ NH ₃] (Sensitizer): Radiosensitization and Toxicity Studies in Vitro," Radiat. Res., 1987, Vol. 112, pp. 273-282.
ST	46	Skov, et al., "Toxicity of [PtCl ₂ (NH ₃) ₂ L] in hypoxia; L=misonidazole or metronidazole," Anticancer Drug Dis., 1990, Vol. 5, pp. 121-128.
ST	47	Skov, et al., "Radiosensitization by metal complexes of 4(5)-nitroimidazole," Int. J. Radiat. Biol., 1990, Vol. 57, pp. 947-958.
ST	48	Herman, et al., "Effect of Hypoxia and Acidosis on the Cytotoxicity of Four Platinum Complexes at Normal and Hyperthermic Temperatures," Cancer Res., 1988, Vol. 48, pp. 2342-2347.
ST	49	Carboni, et al., "Synthesis of a Photoaffinity Analog of Taxol as an Approach to Identify the Taxol Binding Site on Microtubules," J. Med. Chem., 1993, Vol. 36, pp. 513-515.
ST	50	Chen, et al., "Structure-Activity Relationships of Taxol® Synthesis and Biological Evaluation of C2 Taxol Analogs," Bioorg. & Med. Chem. Lett., 1994, Vol. 4, No. 3, pp. 479-482.
ST	51	Rimoldi, et al., "Modified Taxols, 9. Synthesis and Biological Evaluation of 7-Substituted Photoaffinity Analogues of Taxol," J. Nat. Prod., 1993, Vol. 56, pp. 1313-1330.

Examiner Signature		Date Considered	1-02
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

BEST AVAILABLE COPY

O/SB/08A


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if necessary

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Application Number	TBA 09/978,456
				Filing Date	Herewith 10.16.01
				Confirmation Number	TBA
				First Named Inventor	Robert A. Holton
				Group Art Unit	TBA 1625
				Examiner Name	TBA TRINY
Sheet	3	of	3	Attorney Docket No.	FSUM 10595 10551.1

ST	52	Kingston, D. G. I., "The Chemistry of Taxol," Pharmacol. Ther., 1991, Vol. 52, pp. 1-34.	
ST	53	Kingston, D. G. I., "Taxol: The Chemistry and Structure-Activity Relationships of a Novel Anticancer Agent," Trends Biotechnol., 1994, Vol. 12, pp. 222-227.	
ST	54	Nicolaou, et al., "Chemistry and Biology of Taxol," Angew. Chem. Int. Ed. Engl., 1994, Vol. 33, pp. 15-44.	
ST	55	Kingston, et al., "The Chemistry of Taxol, A Clinically Useful Anticancer Agent," J. Nat. Prod., 1990, Vol. 53, No. 1, pp. 1-12.	
BT	56	Guenard, et al. "Taxol and Taxotere: Discovery, Chemistry, and Structure-Activity Relationships," Acc. Chem. Res., 1993, Vol 26, pp. 160-167.	
ST	57	Commercon, et al., "Partial Synthesis of Major Human Metabolites of Docetaxel," Tetrahedron, 1994, Vol. 50, No. 34, pp. 10289-10298.	
ST	58	Stratford, I. J., "Mechanisms of Hypoxic Cell Radiosensitization and the Development of New Sensitizers," Int. J. Radiat. Oncol. Biol. Phys., 1982, Vol. 8, pp. 391-398.	
ST	59	Biaglow, et al. "The Effects of Nitrobenzene Derivatives on Oxygen Utilization and Radiation Response of an in Vitro Tumor Model," Radiat. Res., 1976, Vol. 65, pp. 529-539.	

Examiner Signature		Date Considered	1-02
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

BEST AVAILABLE COPY